Physician profile
Alfredo Torres
NPI 1831226984
$15,398.37
in general payments reported to CMS, 2019-2025
10 companies · $977 in 2025
The $977 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11K · 2022: $2,462 · 2023: $1,113 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,350 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $645 · Food and Beverage: $95.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $645.00 |
| Food and Beverage | $95.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $10,729.89 | 2020 | |
| Genzyme Corporation | $2,440.00 | 2022 | |
| Janssen Biotech, INC. | $1,050.00 | 2023 | Imbruvica |
| Incyte Corporation | $645.00 | 2025 | Monjuvi |
| Abbvie INC. | $300.00 | 2025 | |
| Avanir Pharmaceuticals, INC. | $115.50 | 2020 | |
| Acadia Pharmaceuticals INC | $55.36 | 2023-2025 | Nuplazid |
| Cti Biopharma Corp. | $23.83 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $22.47 | 2022 | |
| Alkermes, INC. | $16.32 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.